41
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Condition(s):Hodgkin DiseaseLast Updated:February 12, 2019Completed
Brentuximab Vedotin: 164 Clinical Trials, Page 5 of 17
Hide Studies Not Open or Pending
42
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease
Condition(s):Graft Versus Host DiseaseLast Updated:June 27, 2013Withdrawn
43
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Condition(s):LymphomaLast Updated:November 27, 2019Terminated
44
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
Condition(s):LymphomaLast Updated:November 4, 2020Recruiting
45
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Condition(s):Aggressive Systemic Mastocytosis; Mast Cell Leukemia; Systemic MastocytosisLast Updated:January 29, 2019Completed
46
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma
Condition(s):Recurrent Classic Hodgkin LymphomaLast Updated:December 17, 2020Not yet recruiting
47
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
Condition(s):Systemic Lupus ErythematosusLast Updated:June 11, 2018Terminated
48
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
Condition(s):Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell LymphomaLast Updated:August 7, 2020Active, not recruiting
49
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Condition(s):LymphomaLast Updated:October 17, 2018Terminated
50
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Condition(s):PTLD; Lymphoid Tumor; Hematopoietic/Lymphoid Cancer; Plasmacytic Hyperplasia PTLD; Infectious Mononucleosis; Florid Follicular Hyperplasia PTLD; Polymorphic PTLD; Monomorphic PTLD; Classical Hodgkin Lymphoma Type PTLDLast Updated:August 13, 2020Withdrawn